Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of empagliflozin (10 mg/kg/day for eight weeks) on the development of NAFLD and its complications using HHTg rats as a non-obese prediabetic rat model. Empagliflozin treatment reduced neutral triacylglycerols and lipotoxic diacylglycerols in the liver and was accompanied by significant changes in relative mRNA expression of lipogenic enzymes (Scd-1, Fas) and transcription factors (Srebp1, Pparγ). In addition, alterations in the gene expression of cytochrome P450 proteins, particularly Cyp2e1 and Cyp4a, together with increased Nrf2, contributed to the improvement of hepatic lipid metabolism after empagliflozin administration. Decreased circulating levels of fetuin-A improved lipid metabolism and attenuated insulin resistance in the liver and in peripheral tissues. Our results highlight the beneficial effect of empagliflozin on hepatic lipid metabolism and lipid accumulation independent of obesity, with the mechanisms understood to involve decreased lipogenesis, alterations in cytochrome P450 proteins, and decreased fetuin-A. These changes help to alleviate NAFLD symptoms in the early phase of the disease and before the onset of diabetes.

Centre for Experimental Medicine Institute for Clinical and Experimental Medicine 14321 Prague Czech Republic

Department of Experimental Hypertension Institute of Physiology Czech Academy of Sciences 14220 Prague Czech Republic

Department of Pharmacology Faculty of Medicine and Dentistry Palacky University Olomouc 77900 Olomouc Czech Republic

Diabetes Centre Institute for Clinical and Experimental Medicine 14321 Prague Czech Republic

Zobrazit více v PubMed

Targher G., Day C.P., Bonora E. Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease. N. Engl. J. Med. 2010;363:1341–1350. doi: 10.1056/NEJMra0912063. PubMed DOI

Kim K.-S., Lee B.-W. Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 2020;26:430–443. doi: 10.3350/cmh.2020.0137. PubMed DOI PMC

Hazlehurst J.M., Tomlinson J. Mechanisms in endocrinology: Non-alcoholic fatty liver disease in common endocrine disorders. Eur. J. Endocrinol. 2013;169:R27–R37. doi: 10.1530/EJE-13-0296. PubMed DOI

Kim D., Kim W.R. Nonobese Fatty Liver Disease. Clin. Gastroenterol. Hepatol. 2017;15:474–485. doi: 10.1016/j.cgh.2016.08.028. PubMed DOI

Patel D.K., Strong J. The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit. Diabetes Ther. 2019;10:1771–1792. doi: 10.1007/s13300-019-00686-z. PubMed DOI PMC

Kuchay M.S., Farooqui K.J., Mishra S.K., Mithal A. Glucose Lowering Efficacy and Pleiotropic Effects of Sodium-Glucose Cotransporter 2 Inhibitors. Adv. Exp. Med. Biol. 2020;1307:213–230. doi: 10.1007/5584_2020_479. PubMed DOI

Kahl S., Gancheva S., Straßburger K., Herder C., Machann J., Katsuyama H., Kabisch S., Henkel E., Kopf S., Lagerpusch M., et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. Diabetes Care. 2019;43:298–305. doi: 10.2337/dc19-0641. PubMed DOI

Chehrehgosha H., Sohrabi M.R., Ismail-Beigi F., Malek M., Babaei M.R., Zamani F., Ajdarkosh H., Khoonsari M., Fallah A.E., Khamseh M.E. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Diabetes Ther. 2021;12:843–861. doi: 10.1007/s13300-021-01011-3. PubMed DOI PMC

Taheri H., Malek M., Ismail-Beigi F., Zamani F., Sohrabi M., Babaei M.R., Khamseh M.E. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Adv. Ther. 2020;37:4697–4708. doi: 10.1007/s12325-020-01498-5. PubMed DOI PMC

Mantovani A., Petracca G., Csermely A., Beatrice G., Targher G. Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites. 2020;11:22. doi: 10.3390/metabo11010022. PubMed DOI PMC

Nasiri-Ansari N., Nikolopoulou C., Papoutsi K., Kyrou I., Mantzoros C.S., Kyriakopoulos G., Chatzigeorgiou A., Kalotychou V., Randeva M.S., Chatha K., et al. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE((−/−)) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis. Int. J. Mol. Sci. 2021;22:818. doi: 10.3390/ijms22020818. PubMed DOI PMC

Petito-Da-Silva T.I., Souza-Mello V., Barbosa-Da-Silva S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. Mol. Cell. Endocrinol. 2019;498:110539. doi: 10.1016/j.mce.2019.110539. PubMed DOI

Perakakis N., Chrysafi P., Feigh M., Veidal S., Mantzoros C. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH. Int. J. Mol. Sci. 2021;22:6332. doi: 10.3390/ijms22126332. PubMed DOI PMC

Zicha J., Pechánová O., Cacányiová S., Cebová M., Kristek F., Török J., Simko F., Dobesová Z., Kunes J. Hereditary hypertriglyceridemic rat: A suitable model of cardiovascular disease and metabolic syndrome? Physiol. Res. 2006;55((Suppl. 1)):49–63. PubMed

Vrána A., Kazdová L. The hereditary hypertriglyceridemic nonobese rat: An experimental model of human hypertriglyceridemia. Transplant. Proc. 1990;22:2579. PubMed

Buzzetti E., Pinzani M., Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metab. Clin. Exp. 2016;65:1038–1048. doi: 10.1016/j.metabol.2015.12.012. PubMed DOI

Schork A., Saynisch J., Vosseler A., Jaghutriz B.A., Heyne N., Peter A., Häring H.-U., Stefan N., Fritsche A., Artunc F. Effect of SGLT2 inhibitors on body composition, fluid status and renin–angiotensin–aldosterone system in type 2 diabetes: A prospective study using bioimpedance spectroscopy. Cardiovasc. Diabetol. 2019;18:1–12. doi: 10.1186/s12933-019-0852-y. PubMed DOI PMC

Ferrannini G., Hach T., Crowe S., Sanghvi A., Hall K.D., Ferrannini E. Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38:1730–1735. doi: 10.2337/dc15-0355. PubMed DOI PMC

Kim J., Lee Y.-J., You Y., Moon M.K., Yoon K., Ahn Y., Ko S. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J. Cell. Biochem. 2019;120:8534–8546. doi: 10.1002/jcb.28141. PubMed DOI

Hojná S., Rauchová H., Malínská H., Marková I., Hüttl M., Papoušek F., Behuliak M., Miklánková D., Vaňourková Z., Neckář J., et al. Antihypertensive and metabolic effects of empagliflozin in Ren-2 transgenic rats, an experimental non-diabetic model of hypertension. Biomed. Pharmacother. 2021;144:112246. doi: 10.1016/j.biopha.2021.112246. PubMed DOI

Iwata K., Kinoshita M., Yamada S., Imamura T., Uenoyama Y., Tsukamura H., Maeda K.-I. Involvement of brain ketone bodies and the noradrenergic pathway in diabetic hyperphagia in rats. J. Physiol. Sci. 2011;61:103–113. doi: 10.1007/s12576-010-0127-6. PubMed DOI PMC

Xu L., Nagata N., Nagashimada M., Zhuge F., Ni Y., Chen G., Mayoux E., Kaneko S., Ota T. SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice. EBioMedicine. 2017;20:137–149. doi: 10.1016/j.ebiom.2017.05.028. PubMed DOI PMC

Guerra S., Gastaldelli A. The role of the liver in the modulation of glucose and insulin in non alcoholic fatty liver disease and type 2 diabetes. Curr. Opin. Pharmacol. 2020;55:165–174. doi: 10.1016/j.coph.2020.10.016. PubMed DOI

Petersen M., Shulman G.I. Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends Pharmacol. Sci. 2017;38:649–665. doi: 10.1016/j.tips.2017.04.004. PubMed DOI PMC

Pokharel A., Kc S., Thapa P., Karki N., Shrestha R., Jaishi B., Paudel M.S. The Effect of Empagliflozin on Liver Fat in Type 2 Diabetes Mellitus Patients With Non-Alcoholic Fatty Liver Disease. Cureus. 2021;13:16687. doi: 10.7759/cureus.16687. PubMed DOI PMC

Lebeaupin C., Vallée D., Hazari Y., Hetz C., Chevet E., Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J. Hepatol. 2018;69:927–947. doi: 10.1016/j.jhep.2018.06.008. PubMed DOI

Kern M., Klöting N., Mark M., Mayoux E., Klein T., Blüher M. The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin. Metabolism. 2016;65:114–123. doi: 10.1016/j.metabol.2015.10.010. PubMed DOI

Endo T., Samokhvalov V., Darwesh A.M., Khey K.M.W., El-Sherbeni A., El-Kadi A.O.S., Machida T., Hirafuji M., Seubert J.M. DHA and 19,20-EDP induce lysosomal-proteolytic-dependent cytotoxicity through de novo ceramide production in H9c2 cells with a glycolytic profile. Cell Death Discov. 2018;4:1–11. doi: 10.1038/s41420-018-0090-1. PubMed DOI PMC

Uno T., Nakano R., Kitagawa R., Okada M., Kanamaru K., Takenaka S., Uno Y., Imaishi H., Kitagawa R. Metabolism of steroids by cytochrome P450 2C9 variants. Biopharm. Drug Dispos. 2018;39:371–377. doi: 10.1002/bdd.2153. PubMed DOI

Eberlé D., Hegarty B., Bossard P., Ferre P., Foufelle F. SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie. 2004;86:839–848. doi: 10.1016/j.biochi.2004.09.018. PubMed DOI

Chambel S.S., Santos-Gonçalves A., Duarte T.L. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism. BioMed Res. Int. 2015;2015:1–10. doi: 10.1155/2015/597134. PubMed DOI PMC

Michel M.C., Mayoux E., Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmiedeberg’s Arch. Pharmacol. 2015;388:801–816. doi: 10.1007/s00210-015-1134-1. PubMed DOI PMC

Wang K., Tan W., Liu X., Deng L., Huang L., Wang X., Gao X. New insight and potential therapy for NAFLD: CYP2E1 and flavonoids. Biomed. Pharmacother. 2021;137:111326. doi: 10.1016/j.biopha.2021.111326. PubMed DOI

Harjumäki R., Pridgeon C., Ingelman-Sundberg M. CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Int. J. Mol. Sci. 2021;22:8221. doi: 10.3390/ijms22158221. PubMed DOI PMC

Leung T.-M., Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J. Hepatol. 2013;58:395–398. doi: 10.1016/j.jhep.2012.08.018. PubMed DOI

Ryu J.-S., Lee M., Mun S.J., Hong S.-H., Lee H.-J., Ahn H.-S., Chung K.-S., Kim G.-H., Son M.J. Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model. J. Biol. Eng. 2019;13:1–14. doi: 10.1186/s13036-019-0198-8. PubMed DOI PMC

Zhang X., Li S., Zhou Y., Su W., Ruan X., Wang B., Zheng F., Warner M., Gustafsson J.-Å., Guan Y. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis. Proc. Natl. Acad. Sci. USA. 2017;114:3181–3185. doi: 10.1073/pnas.1700172114. PubMed DOI PMC

Huang B., Bao J., Cao Y.-R., Gao H.-F., Jin Y. Cytochrome P450 1A1 (CYP1A1) Catalyzes Lipid Peroxidation of Oleic Acid-Induced HepG2 Cells. Biochemistry. 2018;83:595–602. doi: 10.1134/S0006297918050127. PubMed DOI

Meex R.C.R., Watt M.J. Hepatokines: Linking nonalcoholic fatty liver disease and insulin resistance. Nat. Rev. Endocrinol. 2017;13:509–520. doi: 10.1038/nrendo.2017.56. PubMed DOI

Dogru T., Kirik A., Gurel H., Rizvi A., Rizzo M., Sonmez A. The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. Int. J. Mol. Sci. 2021;22:6627. doi: 10.3390/ijms22126627. PubMed DOI PMC

Mori K., Emoto M., Inaba M. Fetuin-A: A multifunctional protein. Recent Pat. Endocr. Metab. Immune Drug Discov. 2011;5:124–146. doi: 10.2174/187221411799015372. PubMed DOI

Lee K.-Y., Lee W., Jung S.-H., Park J., Sim H., Choi Y.-J., Park Y.-J., Chung Y., Lee B.-H. Hepatic upregulation of fetuin-A mediates acetaminophen-induced liver injury through activation of TLR4 in mice. Biochem. Pharmacol. 2019;166:46–55. doi: 10.1016/j.bcp.2019.05.011. PubMed DOI

Ke Y., Xu C., Lin J., Li Y. Role of hepatokines in non-alcoholic fatty liver disease. J. Transl. Intern. Med. 2019;7:143–148. doi: 10.2478/jtim-2019-0029. PubMed DOI PMC

Su X., Kong Y., Peng D. Fibroblast growth factor 21 in lipid metabolism and non-alcoholic fatty liver disease. Clin. Chim. Acta. 2019;498:30–37. doi: 10.1016/j.cca.2019.08.005. PubMed DOI

Yilmaz Y., Eren F., Yonal O., Kurt R., Aktas B., Celikel C.A., Ozdogan O., Imeryuz N., Kalayci C., Avsar E. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur. J. Clin. Investig. 2010;40:887–892. doi: 10.1111/j.1365-2362.2010.02338.x. PubMed DOI

Ashino T., Ohkubo-Morita H., Yamamoto M., Yoshida T., Numazawa S. Possible involvement of nuclear factor erythroid 2-related factor 2 in the gene expression of Cyp2b10 and Cyp2a5. Redox Biol. 2014;2:284–288. doi: 10.1016/j.redox.2013.12.025. PubMed DOI PMC

Abdelhamid A.M., Elsheakh A.R., Abdelaziz R.R., Suddek G.M. Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-κB/Nrf-2/PPAR-γ interplay in mice. Life Sci. 2020;256:117908. doi: 10.1016/j.lfs.2020.117908. PubMed DOI

Malinska H., Hüttl M., Oliyarnyk O., Bratova M., Kazdova L. Conjugated linoleic acid reduces visceral and ectopic lipid accumulation and insulin resistance in chronic severe hypertriacylglycerolemia. Nutrition. 2015;31:1045–1051. doi: 10.1016/j.nut.2015.03.011. PubMed DOI

Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia

Gliflozins in the Treatment of Non-diabetic Experimental Cardiovascular Diseases

Hypolipidemic Effects of Beetroot Juice in SHR-CRP and HHTg Rat Models of Metabolic Syndrome: Analysis of Hepatic Proteome

Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes